Astrazeneca acquires the US Fusion for over 2 billion
Astrazeneca has announced the purchase of the US cancer radiopharmaceutical company Fusion, a biopharmaceutical company developing next-generation radioconjugates (RCs), for a maximum sum of 2.4 billion dollars.
Under the terms of the definitive agreement, AstraZeneca through a subsidiary will acquire all shares of Fusion. Agreement reached on the basis of $21 for each: plus a non-transferable contingent value right of three dollars payable upon reaching a certain regulatory milestone.
“The acquisition marks an important step forward in realizing its ambition to transform cancer treatment and patient outcomes,” the company said in a statement. replacing traditional treatments such as chemotherapy and radiotherapy with more targeted treatments“. Radioconjugates in recent years are becoming a promising modality in the treatment of cancer. These medicines release a radioactive isotope directly into tumor cells through a precise target and using molecules such as antibodies, peptides or small molecules.